PortfoliosLab logoPortfoliosLab logo
GILD vs. JNJ
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

GILD vs. JNJ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gilead Sciences, Inc. (GILD) and Johnson & Johnson (JNJ). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

GILD vs. JNJ - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GILD
Gilead Sciences, Inc.
14.96%36.59%18.68%-1.99%23.63%29.95%-6.70%7.88%-9.92%2.96%
JNJ
Johnson & Johnson
18.59%47.48%-4.81%-8.58%5.97%11.44%10.82%16.22%-5.13%24.43%

Fundamentals

Market Cap

GILD:

$175.80B

JNJ:

$595.41B

EPS

GILD:

$6.79

JNJ:

$11.04

PE Ratio

GILD:

20.67

JNJ:

22.12

PEG Ratio

GILD:

0.05

JNJ:

0.74

PS Ratio

GILD:

5.98

JNJ:

6.29

PB Ratio

GILD:

7.77

JNJ:

7.30

Total Revenue (TTM)

GILD:

$29.44B

JNJ:

$94.19B

Gross Profit (TTM)

GILD:

$23.79B

JNJ:

$68.56B

EBITDA (TTM)

GILD:

$12.90B

JNJ:

$39.85B

Returns By Period

In the year-to-date period, GILD achieves a 14.96% return, which is significantly lower than JNJ's 18.59% return. Over the past 10 years, GILD has underperformed JNJ with an annualized return of 7.81%, while JNJ has yielded a comparatively higher 11.40% annualized return.


GILD

1D
0.67%
1M
-5.95%
YTD
14.96%
6M
27.78%
1Y
29.43%
3Y*
23.25%
5Y*
20.53%
10Y*
7.81%

JNJ

1D
-0.13%
1M
-1.79%
YTD
18.59%
6M
32.75%
1Y
63.73%
3Y*
19.86%
5Y*
11.54%
10Y*
11.40%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GILD vs. JNJ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GILD
GILD Risk / Return Rank: 7373
Overall Rank
GILD Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
GILD Sortino Ratio Rank: 7070
Sortino Ratio Rank
GILD Omega Ratio Rank: 6464
Omega Ratio Rank
GILD Calmar Ratio Rank: 7777
Calmar Ratio Rank
GILD Martin Ratio Rank: 7878
Martin Ratio Rank

JNJ
JNJ Risk / Return Rank: 9797
Overall Rank
JNJ Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
JNJ Sortino Ratio Rank: 9898
Sortino Ratio Rank
JNJ Omega Ratio Rank: 9898
Omega Ratio Rank
JNJ Calmar Ratio Rank: 9595
Calmar Ratio Rank
JNJ Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GILD vs. JNJ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GILDJNJDifference

Sharpe ratio

Return per unit of total volatility

1.02

3.67

-2.65

Sortino ratio

Return per unit of downside risk

1.63

4.95

-3.32

Omega ratio

Gain probability vs. loss probability

1.19

1.67

-0.48

Calmar ratio

Return relative to maximum drawdown

2.07

6.09

-4.02

Martin ratio

Return relative to average drawdown

5.62

20.41

-14.79

GILD vs. JNJ - Sharpe Ratio Comparison

The current GILD Sharpe Ratio is 1.02, which is lower than the JNJ Sharpe Ratio of 3.67. The chart below compares the historical Sharpe Ratios of GILD and JNJ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


GILDJNJDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.02

3.67

-2.65

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.86

0.70

+0.17

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.31

0.62

-0.32

Sharpe Ratio (All Time)

Calculated using the full available price history

0.39

0.54

-0.15

Correlation

The correlation between GILD and JNJ is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

GILD vs. JNJ - Dividend Comparison

GILD's dividend yield for the trailing twelve months is around 2.27%, more than JNJ's 2.13% yield.


TTM20252024202320222021202020192018201720162015
GILD
Gilead Sciences, Inc.
2.27%2.57%3.33%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%
JNJ
Johnson & Johnson
2.13%2.48%3.40%3.00%2.52%2.45%2.53%2.57%2.74%2.38%2.73%2.87%

Drawdowns

GILD vs. JNJ - Drawdown Comparison

The maximum GILD drawdown since its inception was -70.83%, which is greater than JNJ's maximum drawdown of -50.67%. Use the drawdown chart below to compare losses from any high point for GILD and JNJ.


Loading graphics...

Drawdown Indicators


GILDJNJDifference

Max Drawdown

Largest peak-to-trough decline

-70.83%

-50.67%

-20.16%

Max Drawdown (1Y)

Largest decline over 1 year

-13.77%

-8.42%

-5.35%

Max Drawdown (5Y)

Largest decline over 5 years

-26.59%

-18.41%

-8.18%

Max Drawdown (10Y)

Largest decline over 10 years

-36.01%

-27.37%

-8.64%

Current Drawdown

Current decline from peak

-9.44%

-1.79%

-7.65%

Average Drawdown

Average peak-to-trough decline

-22.20%

-11.89%

-10.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.08%

2.51%

+2.57%

Volatility

GILD vs. JNJ - Volatility Comparison

Gilead Sciences, Inc. (GILD) has a higher volatility of 6.36% compared to Johnson & Johnson (JNJ) at 4.43%. This indicates that GILD's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


GILDJNJDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.36%

4.43%

+1.93%

Volatility (6M)

Calculated over the trailing 6-month period

18.91%

10.94%

+7.97%

Volatility (1Y)

Calculated over the trailing 1-year period

29.01%

19.11%

+9.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

23.90%

16.67%

+7.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

25.63%

18.33%

+7.30%

Financials

GILD vs. JNJ - Financials Comparison

This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B15.00B20.00B25.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
7.93B
24.56B
(GILD) Total Revenue
(JNJ) Total Revenue
Values in USD except per share items

GILD vs. JNJ - Profitability Comparison

The chart below illustrates the profitability comparison between Gilead Sciences, Inc. and Johnson & Johnson over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

65.0%70.0%75.0%80.0%85.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
86.8%
86.4%
Portfolio components
GILD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported a gross profit of 6.88B and revenue of 7.93B. Therefore, the gross margin over that period was 86.8%.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported a gross profit of 21.22B and revenue of 24.56B. Therefore, the gross margin over that period was 86.4%.

GILD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported an operating income of 2.96B and revenue of 7.93B, resulting in an operating margin of 37.4%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported an operating income of 5.39B and revenue of 24.56B, resulting in an operating margin of 22.0%.

GILD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported a net income of 2.18B and revenue of 7.93B, resulting in a net margin of 27.6%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported a net income of 5.12B and revenue of 24.56B, resulting in a net margin of 20.8%.